Impact of new hepatitis c treatments in different regions of the world

Gastroenterology

Volumn 146, Issue 5, 2014, Pages

  Wei, Lai ^a,b   Lok, Anna S F ^b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 333; ABT 450; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; FALDAPREVIR; INTERLEUKIN 28B; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ANTIVIRAL ACTIVITY; B CELL LYMPHOMA; CRYOGLOBULINEMIA; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DEVELOPED COUNTRY; DIABETES MELLITUS; DISEASE COURSE; DRUG USE; EGYPT; FOOD AND DRUG ADMINISTRATION; GENERAL PRACTITIONER; GENOTYPE; GLOMERULONEPHRITIS; HEALTH CARE QUALITY; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INDIA; INFECTION; INSULIN RESISTANCE; JAPAN; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER INJURY; LIVER TRANSPLANTATION; LOWEST INCOME GROUP; NOTE; PAKISTAN; PATIENT ADVOCACY; PATIENT SAFETY; PERSONAL EXPERIENCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; QUALITY OF LIFE; SIDE EFFECT; TAIWAN; TREATMENT DURATION; WORLD HEALTH ORGANIZATION;

ANTIVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEALTH SERVICES ACCESSIBILITY; HEPACIVIRUS; HEPATITIS C; HUMANS; PATIENT SELECTION; PHENOTYPE; PREVALENCE; STANDARD OF CARE; TREATMENT OUTCOME; WORLD HEALTH;

EID: 84898973721     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.03.008     Document Type: Editorial

References (68)

1. K. Mohd Hanafiah, J. Groeger, and A.D. Flaxman et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 2013 1333 1342
2. G.L. Armstrong, A. Wasley, and E.P. Simard et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 2006 705 714
3. D. Lavanchy Evolving epidemiology of hepatitis C virus Clin Microbiol Infect 17 2011 107 115
4. C. Wartelle-Bladou, G. Le Folgoc, and M. Bourlière et al. Hepatitis C therapy in non-genotype 1 patients: the near future J Viral Hepat 19 2012 525 536
5. E. Bugianesi, F. Salamone, and F. Negro The interaction of metabolic factors with HCV infection: does it matter? J Hepatol 56 Suppl 1 2012 S56 S65
6. A.J. van der Meer, B.J. Veldt, and J.J. Feld et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
7. L.I. Backus, D.B. Boothroyd, and B.R. Phillips et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C Clin Gastroenterol Hepatol 9 2011 509 516
8. R. Chou, E.B. Cottrell, and N. Wasson et al. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force Ann Intern Med 158 2013 101 108
9. D. Ge, J. Fellay, and A.J. Thompson et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
10. Y. Tanaka, N. Nishida, and M. Sugiyama et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
11. D.L. Thomas, C.L. Thio, and M.P. Martin et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
12. C.F. Huang, J.F. Huang, and J.F. Yang et al. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin J Hepatol 56 2012 34 40
13. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
14. F. Poordad, J. McCone Jr., and B.R. Bacon et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
15. C1 Hézode, H. Fontaine, and C. Dorival et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441
16. J.M. Pawlotsky New hepatitis C therapies: the toolbox, strategies, and challenges Gastroenterology 146 2014 1176-1192
17. M.P. Manns, and T. von Hahn Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 12 2013 595 610
18. M.L. Volk, R. Tocco, and S. Saini et al. Public health impact of antiviral therapy for hepatitis C in the United States Hepatology 50 2009 1750 1755
19. S.D. Holmberg, P.R. Spradling, and A.C. Moorman et al. Hepatitis C in the United States N Engl J Med 368 2013 1859 1861
20. A. Hatzakis, S. Wait, and J. Bruix et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference J Viral Hepat 18 Suppl 1 2011 1 16
21. B. Lettmeier, N. Mühlberger, and R. Schwarzer et al. Market uptake of new antiviral drugs for the treatment of hepatitis C J Hepatol 49 2008 528 536
22. B.D. Smith, R.L. Morgan, and G.A. Beckett et al. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention Ann Intern Med 157 2012 817 822
23. Knox R. $1,000 pill for hepatitis C spurs debate over drug prices. Available at: http://www.npr.org/blogs/health. Accessed December 30, 2013.
24. S. Liu, L.E. Cipriano, and M. Holodniy et al. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis Ann Intern Med 156 2012 279 290
25. Datta J. Gilead, local generic players in talks to bring hepatitis C drug into India. Available at: http://www.thehindubusinessline.com. Published February 3, 2014.
26. Pawlotsky JM. An interview with Professor Jean-Michel Pawlotsky on how the treatment of HCV infection will change in the near future as a result of recent developments. Available at: http://www.hepbcppa.org/newsletter. Published December 2013.
27. Y. Suzuki, K. Ikeda, and F. Suzuki et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options J Hepatol 58 2013 655 662
28. M. Cornberg, H.A. Razavi, and A. Alberti et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel Liver Int 31 Suppl 2 2011 30 60
29. W. Sievert, I. Altraif, and H.A. Razavi et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt Liver Int 31 Suppl 2 2011 61 80
30. C.J. Murray, M. Ezzati, and A.D. Flaxman et al. GBD 2010: design, definitions, and metrics Lancet 380 2012 2063 2066
31. M.M. Manos, V.A. Shvachko, and R.C. Murphy et al. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population J Med Virol 84 2012 1744 1750
32. Marotta P, Cooper CL, Wong DK, et al. Impact of advanced fibrosis and cirrhosis on sustained virologic response of HCV G1-infected patients: results of the Canadian power program (Abstract #1216). 58th annual meeting of the American Association for the Study of Liver Diseases, 31 October-4 November 2008. San Francisco, California, USA. Hepatology 2008;48(Suppl 1):849A.
33. D. Huppe, E. Zehnter, and S. Mauss et al. Epidemiology of chronic hepatitis C in Germany-an analysis of 10,326 patients in hepatitis centres and outpatient units Z Gastroenterol 46 2008 34 44
34. Costella, Annastella and Health Protection Agency United Kingdom. Hepatitis C in the UK 2008. The Health Protection Agency Annual Report. London: Health Protection Agency Centre for Infections, 2008.
35. L. Prasad, V.M. Spicher, and M. Zwahlen et al. Cohort profile: the Swiss Hepatitis C Cohort Study (SCCS) Int J Epidemiol 36 2007 731 737
36. C. Payan, F. Roudot-Thoraval, and P. Marcellin et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millennium: The GEMHEP GenoCII Study J Viral Hepat 12 2005 405 413
37. M. Raptopoulou, G. Touloumi, and D. Tzourmakliotis et al. Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study Hippokratia 15 2011 26 31
38. J.M. Echevarria, P. Leon, and F. Pozo et al. Follow-up of the prevalence of hepatitis C virus genotypes in Spain during a nine-year period (1996-2004) Enferm Infecc Microbiol Clin 24 2006 20 25
39. A. Panasiuk, R. Flisiak, and I. Mozer-Lisewska et al. Distribution of HCV genotypes in Poland Przegl Epidemiol 67 2013 99 103
40. C. Sultana, G. Oprisan, and C. Szmal et al. Molecular epidemiology of hepatitis C virus strains from Romania J Gastrointest Liver Dis 20 2011 261 266
41. A.V. Shustov, G.V. Kochneva, and G.F. Sivolobova et al. Molecular epidemiology of the hepatitis C virus in Western Siberia J Med Virol 77 2005 382 389
42. E.J. Cho, S.H. Jeong, and B.H. Han et al. Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience Clin Mol Hepatol 18 2012 219 224
43. H. Rao, L. Wei, and J. Lopez-Talavera et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection J Gastroenterol Hepatol 29 2014 545 553
44. D.A. Pham, P. Leuangwutiwong, and A. Jittmittraphap et al. High prevalence of hepatitis C virus genotype 6 in Vietnam Asian Pac J Allergy Immunol 27 2009 153 160
45. S. Kageyama, D.M. Agdamag, and E.T. Alesna et al. Tracking the entry routes of hepatitis C virus as a surrogate of HIV in an HIV-low prevalence country, the Philippines J Med Virol 81 2009 1157 1162
46. D. Kanistanon, M. Neelamek, and T. Dharakul et al. Genotypic distribution of hepatitis C virus in different regions of Thailand J Clin Microbiol 35 1997 1772 1776
47. A. Utama, N.P. Tania, and R. Dhenni et al. Genotype diversity of hepatitis C virus (HCV) in HCV-associated liver disease patients in Indonesia Liver Int 30 2010 1152 1160
48. A.A. Lwin, T. Shinji, and M. Khin et al. Hepatitis C virus genotype distribution in Myanmar: predominance of genotype 6 and existence of new genotype 6 subtype Hepatol Res 37 2007 337 345
49. S. Narahari, A. Juwle, and S. Basak et al. Prevalence and geographic distribution of Hepatitis C Virus genotypes in Indian patient cohort Infect Genet Evol 9 2009 643 645
50. S. Attaullah, S. Khan, and I. Ali Hepatitis C virus genotypes in Pakistan: a systemic review Virol J 8 2011 433
51. S. Kaba, U. Dutta, and K. Byth et al. Molecular epidemiology of hepatitis C in Australia J Gastroenterol Hepatol 13 1998 914 920
52. H. Sharafi, A. Pouryasin, and S.M. Alavian et al. Distribution of IL28B genotypes in Iranian patients with chronic hepatitis C and healthy individuals Hepat Mon 12 2012 e8387
53. O.A. Shobokshi, F.E. Serebour, and L.I. Skakni Hepatitis C genotypes/subtypes among chronic hepatitis patients in Saudi Arabia Saudi Med J 24 Suppl 2 2003 S87 S91
54. I. Altuglu, I. Soyler, and T. Ozacar et al. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey Int J Infect Dis 12 2008 239 244
55. M. Abdel-Hamid, M. El-Daly, and V. Molnegren et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma J Gen Virol 88 2007 1526 1531
56. R. Jimenez-Mendez, F. Uribe-Salas, and P. López-Guillen et al. Distribution of HCV genotypes and HCV RNA viral load in different regions of Mexico Ann Hepatol 9 2010 33 39
57. D.S. Vieira, M.V. Alvarado-Mora, and L. Botelho et al. Distribution of hepatitis c virus (HCV) genotypes in patients with chronic infection from Rondonia, Brazil Virol J 8 2011 165
58. N. del Pino, J.R. Oubiña, and F. Rodríguez-Frías et al. Molecular epidemiology and putative origin of hepatitis C virus in random volunteers from Argentina World J Gastroenterol 19 2013 5813 5827
59. A.J. Thompson, A.J. Muir, and M.S. Sulkowski et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 2010 120 129
60. A. Mangia, A.J. Thompson, and R. Santoro et al. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring Hepatology 54 2011 772 780
61. I. Sporea, A. Popescu, and M. Curescu et al. The correlation of IL28B genotype with sustained virologic response in Romanian patients with chronic hepatitis C Hepat Mon 11 2011 975 979
62. D.L. Thomas, C.L. Thio, and M.P. Martin et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
63. M. Kobayashi, F. Suzuki, and N. Akuta et al. Association of two polymorphisms of the IL28B gene with viral factors and treatment response In 1,518 patients infected with hepatitis C virus Gastroenterology 47 2012 596 605
64. K. Lyoo, M.J. Song, and W. Hur et al. Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin J Clin Virol 52 2011 363 366
65. S.K. Roberts, J. Mitchell, and R. Leung et al. Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies J Gastroenterol Hepatol 29 2014 179 184
66. S. Ezzikouri, R. Alaoui, and K. Rebbani et al. Genetic variation in the interleukin-28B gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patients PLoS ONE 8 2013 e54793
67. L.N. Cavalcante, K. Abe-Sandes, and A.L. Angelo et al. IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population Liver Int 32 2012 476 486
68. E. Ridruejo, A. Solano, and S. Marciano et al. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin Ann Hepatol 10 2011 452 457